Zydus Lifesciences gets final USFDA nod to market generic Micafungin injection

NEW DELHI, Oct 26: Zydus Lifesciences on Wednesday said it has received final approval from the US health regulator to market its generic Micafungin injection, used to treat a variety of fungal infections.
The approval granted by the US Food and Drug Administration (USFDA) to market Micafungin for Injection is for strengths of 50 mg/vial and 100 mg/vial, single-dose vials, Zydus Lifesciences Ltd said in a regulatory filing.
Micafungin for injection is indicated to treat a variety of fungal infections. It is also used to prevent fungal infections in patients who are having a stem-cell transplant.
“The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, India,” it added.
Micafungin for injection had annual sales of USD 99 million in the US, the company said citing IQVIA MAT August 2022 data. (PTI)